Dr. Atlas on the Current Treatment Paradigm in CSCC


Jennifer L. Atlas, MD, discusses the ​current cutaneous squamous cell carcinoma treatment paradigm.

Jennifer L. Atlas, MD, a medical oncologist specializing in lung cancer at Levine Cancer Institute, Carolinas HealthCare System/Atrium Health, discusses the ​current cutaneous squamous cell carcinoma (CSCC)​ treatment paradigm.

The standard of care for patients with local​ly advanced CSCC is surgical resection, says Atlas.

The majority of patients with low-risk CSCC will undergo surgical resection, Atlas explains. However, whether systemic therapies provide additional benefit to surgical resection is not well defined.

However, in situations where the disease cannot be ​fully resected or ​the patient is considered to be at high risk for surgery, systemic therapies such as cemiplimab​-rwlc ​(Libtayo) ​should be considered, Atlas concludes. 

Related Videos
Jane L. Meisel, MD, Emory University
Jeffrey Zonder, MD
Jun Gong, MD
John Michael Bryant, MD,
Chandler H. Park, MD, FACP
Kathryn Beckermann, MD, PhD
Eleonora Dondossola, PhD
William B. Pearse, MD
Pasi A. Jänne, MD, PhD, director, Lowe Center for Thoracic Oncology, director, Belfer Center for Applied Cancer Science, director, Chen-Huang Center for EGFR Mutant Lung Cancers, senior physician, David M. Livingston, MD, Chair, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Rachid Baz, MD, section head, Myeloma, Department of Malignant Hematology, Moffitt Cancer Center; co-director, Pentecost Family Myeloma Research Center